Abstract
The cure from Alzheimer's disease is a challenging mission. Acetylcholinesterase enzyme (AChE) inhibitors, including tacrine, are considered the most important line for Alzheimer's therapy. In the current study, we aimed at designing and synthesizing new thienopyridine-tacrine analogues. The molecular structures of the synthesized compounds were illustrated by spectroscopic and elemental analysis. These compounds have been screened for their in vivo brain acetyl cholinesterase inhibition activities. The majority of the tested compounds exhibited inhibitory activity towards AChE. The IC50 for the most promising members was determined in vitro. Interestingly, compound 11a displayed the best profile with IC50 of about 172 nM.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
